🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prophylactic Irradiation to the Contralateral Breast for BCAs Patients

RecruitingNAAges 30 Years - 70 YearsFemaleSecond Affiliated Hospital, Zhejiang University, …
NCT04960839 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Breast cancer is the most common cancer in women worldwide, with high mortality. About 5% to 10% of breast cancers are hereditary. Most inherited cases of breast cancer are associated with germline mutations in genes, such as BRCA1, BRCA2 and PALB2. The cumulative breast cancer risk for BRCA1, BRCA2 or PALB2 mutation carriers was high. Besides the increased breast cancer risk for the inherited mutation carriers, the risk of subsequent contralateral breast cancer for the mutation carriers with breast cancer was also significantly increased. Contralateral prophylactic mastectomy was usually recommended to the breast cancer patients with BRCA mutation. However, many breast cancer patients refused the contralateral prophylactic mastectomy, due to the surgical injury, potential surgical complications, deleteriously affected body image and sexuality. Solid evidence validated that radiotherap

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Female patients, aged 30-70yrs, diagnosed with stage 0-III breast cancer (NCCN-Breast Cancer V2.2019), undergoing the lumpectomy or mastectomy no more than 1 year. ALND or SLNB should be carried out and the lymph node status should be known. * Patients with a deleterious germline mutation of BRCA 1/2 or PALB2. * The patients with no contraindictation for irradiation. * The patients consent for prophylactic irradiation to the contralateral breast. * The patient may receive any regimen of adjuvant, neoadjuvant chemotherapy, according to the treating physician. The radiation therapy should start at least 2 weeks after the completion of all the chemotherapy cycles. * The patient may receive endocrine therapy before, during or after study entry. * The patient may receive target therapy (Trastuzumab) before, during or after study entry. * The patient must be eligible for MRI examination of the contralateral breast. * The patient refused prophylactic contralateral mastectomy and oophorectomy. Exclusion Criteria: * Metastatic breast cancer. * Past history of other cancer besides breast cancer * Previous irradiation of the breast or chest wall, but not for breast cancer treatment * Synchronous bilateral breast cancer * Patients with active connective tissue diseases, pneumonia are excluded due to the potential risk of significant radiotherapeutic toxicity.
💊

What it tests

  • Prophylactic contralateral breast irradiation
📍

Where

8 sites
Department of Breast Surgery, Jiangxi Provincial Cancer Hospital
Jiangxi, China
Department of Breast Surgery, Obestrics and Gynecology Hospital of Fudan University
Shanghai, China
Department of Breast Surgery, Cancer Hospital of University of Chinese Academy of Sciences
Hangzhou, China
Department of Breast Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, China
Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University
Hangzhou, China
Department of Oncology, Zhejiang Hospital
Hangzhou, China
Department of Breast Surgery, Yong Loo Lin School of Medicine, National University of Singapore
Singapore, Singapore
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy